Active Ingredient Group For Treating Constipation
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Mar 13, 2025
app pub date -
Dec 6, 2023
filing date -
Dec 6, 2023
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention belongs to the field of medical technology and specifically relates to an active ingredient group for treating constipation. An active ingredient group for treating constipation, characterized in that the active ingredient group includes rhein, hesperetin, albiflorin, and magnolol. The key target combination of constipation includes RXRA, CYP1A1, CYP1A2 and PLA2G4. The active ingredient group for treating constipation provided in this application can effectively prevent and treat constipation by regulating bile acid secretion, steroid hormone biosynthesis, glycerophospholipid metabolism, and linoleic acid metabolism by establishing strong combination between the active ingredient group and the key target combination of constipation. This application also discloses the biomarkers for the diagnosis and treatment of constipation.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully